Rapid adoption of Carterra’s LSA instrument drives European expansion20 Aug 2019
Company's antibody screening platform minimizes the risk of missing a blockbuster.
Carterra has opened a Customer Experience Center (CEC) and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.
The Munich CEC will be a place for researchers throughout Europe to gain first-hand experience with Carterra’s game-changing antibody screening platform, the LSA, through demonstrations and workshops. Carterra will also offer basic courses in label-free biosensor operation, experimental design, and data analysis. Since its launch in 2018, the LSA is installed on three continents and in a majority of the largest pharmaceutical companies in the world. To support this exponential worldwide growth, Carterra has hired direct sales, support, and service personnel in Europe, most of whom are based in the Munich office.
Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries by low-resolution “yes/no” assays to identify binders. Only a small group of candidate antibodies are then characterized on traditional, low-throughput biosensor tools, which provide real-time readout of the full binding profile. This workflow runs the risk that potential blockbuster drug candidates could be missed.
Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a blockbuster. The LSA’s dramatic throughput condenses months of work into days.
Additionally, the LSA offers investigators the most resolved view of the epitope – the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level. This provides biologics developers an enormous advantage in differentiating their biomolecules from competitors’ drugs and in establishing intellectual property claims.
“The LSA is changing the way biologics are discovered,” says Tim Germann, Carterra’s Chief Commercial Officer. “We’re thrilled to invite European drug developers and the research community at large to experience in person the massive throughput and minuscule sample requirements that the LSA enables. We’re making the traditional discovery processes up to 100 times faster while using only 1% of the normal sample input-it’s the definition of disruptive.”
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Dutch company receives €20 million for skin cancer diagnostic test
3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.Read more
AbbVie axes Rovalpituzumab Tesirine R&D program
2 Sep 2019
Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.Read more
Improving anxiety-induced insomnia with lavender oil
29 Aug 2019
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.Read more
Grant from Innovate UK to fund gel stabilisation technologies development
28 Aug 2019
Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.Read more
Exciting new vaccine targets killer disease TB
28 Aug 2019
Australian researchers produce early-stage vaccine which is inhaled into the lungs.Read more
IDT launches oPools Oligo Pools
19 Aug 2019
The longest, highest fidelity, and ready-to-use custom oligo pools on the market.Read more
FDA Approves rfxcel for Verification Router Service (VRS) Pilot
15 Aug 2019
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.Read more
rfxcel Awarded ISO 9001:2015 Certification
14 Aug 2019
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation